News
AUSTIN, TX / ACCESS Newswire / August 22, 2025 / Action Behavior Centers (ABC), a leading provider of evidence-based applied behavior analysis (ABA) therapy for children diagnosed with autism spectrum ...
PENSACOLA, FLORIDA / ACCESS Newswire / August 22, 2025 / Emergency Care Partners ("ECP"), a leading national emergency medicine services provider, announced today the completion of a strategic merger ...
The global prescription lens market is expected to grow at a CAGR of ~5% during the forecast period. Rising prevalence of ...
The Global Pain Management Devices Market is expected to grow at the rate of 9-10 % by 2029. Growing cases of chronic ...
The global mice model market is set to witness a growth rate of ~9% in the next 5 years. Increasing demand for personalized ...
The global sepsis diagnostics market is set to witness a growth rate of ~7% in the next 5 years. High incidence of sepsis ...
TORONTO, ON / ACCESS Newswire / August 22, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), announces that it has entered into a letter of intent (the "LOI") to acquire all of the ...
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna announced today that Health Canada has ...
IAPMO R&T and QFT Laboratory conducted testing to NSF standards. LONDON, UK / ACCESS Newswire / August 22, 2025 / Independent laboratory testing of Klar Water Filters was carried out by IAPMO R&T and ...
BOULDER, CO / ACCESS Newswire / August 22, 2025 / Encision Inc. (OTC PINK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant ...
GOTHENBURG, SE / ACCESS Newswire / August 22, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced ...
STOCKHOLM, SE / ACCESS Newswire / August 22, 2025 / Vicore Pharma Holding AB (STO: VICO) ("Vicore"), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results